November 14, 2019: Efficacy and Safety of Minimally Invasive Surgery with Thrombolysis in Intracerebral Haemorrhage Evacuation (MISTIE III)

36:54
 
Share
 

Manage episode 246205019 series 1459666
By Education Neurocritical Care and Neurocritical Care Society. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Dr. Fawaz Al-Mufti is joined by Dr. Daniel Hanley and Dr. Issam Awad to discuss Dr. Hanley's recent article, "Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial." This podcast is sponsored by the TTM Academy program at Penn Medicine, an educational initiative to improve care for patients following cardiac arrest and other eurocritical illness using targeted temperature management. This includes live CME workshops, an on-line video educational program, and a free podcast program. Find out more at www.pennttm.com.

The NCS Podcast is the official podcast of the Neurocritical Care Society. Our senior producer is Bonnie Rossow. Our host is Fawaz Almufti, and our production staff includes Ramani Balu, Michael Brogan, Joshua Levine, Sarah Stern-Nezer, Benjamin Miller, Starane Shepherd, and Chris Zammit. Our administrative staff include Becca Stickney, Sara Memmen, and Angel Gindele. Music by Mohan Kottapally.

NCS offers free CE credits for the NCS Podcast Series episodes. Listen to any of the posted episodes, complete a five question survey, and claim your credits here! Credits are available for physicians, pharmacists, nurses, and non-physicians.

Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, et al. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019 Mar 9;393(10175):1021-1032.

68 episodes